Thrombin as a common downstream target blocking both platelet and monocyte activation

• References

• 1 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
• 2 Becker RC, Meade TW, Berger PB. et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 776S-814S.
• 3 Marcucci R, Paniccia R, Antonucci E. et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98: 844-851.
• 4 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
• 5 Landolfi R, De Candia E, Rocca B. et al. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis “in vivo". Thromb Haemost 1994; 72: 942-946.
• 6 Anand SX, Kim MC, Kamran M. et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007; 100: 417-424.
• 7 Ciabattoni G, Ujang S, Sritara P. et al. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. J Am Coll Cardiol 1993; 21: 1377-1381.
• 8 Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 2002; 13: 161-165.
• 9 Kastrati A, Neumann FJ, Mehilli J. et al. ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696.
• 10 Geisler T, Grass D, Bigalke B. et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
• 11 Sibbing D, Busch G, Braun S. et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008; 29: 1504-1509.
• 12 Keating FK, Dauerman HL, Whitaker DA. et al. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118: 361-369.
• 13 Undas A, Szuldrzynski K, Brummel-Ziedins KE. et al. Systemic blood coagulation activation in acute coronary syndromes. Blood. 2008 epub ahead of print.
• 14 Ferroni P, Santilli F, Guadagni F, Basili S, Davì G. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem 2007; 14: 2170-2180.
• 15 Busch G, Steppich B, Sibbing D. et al. Thromb Haemost 2009; 101: 340-344.
• 16 Busch G, Seitz I, Steppich B. et al. Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005; 25: 461-466.
• 17 Li G, Keenan AC, Young JC. et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirudin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol 2007; 27: 1850-1856.
• 18 Kim S, Foster C, Lecchi A. et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002; 99: 3629-3636.
• 19 Hurlen M, Abdelnoor M, Smith P. et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974.
• 20 Wagner D, Frenette S. The vessel wall and its interations. Blood 2008; 111: 5271-5281.
• 21 Kipshidze N, Dangas G, Tsapenko M. et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 2004; 44: 733-739.